Melbourne, Feb 19, 2009 AEST (ABN Newswire) - Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) Net loss after tax was A$1.9 million, with operating cash outflows of A$2.5 million for the half year, 12% less than the same period in the prior year. Cash at 31 December was A$6.1 million. Total revenue and other income was A$5.1 million for the half year with revenue from continuing operations A$1.0 million for the six months, up 6% compared with the same period in the prior year.
Receipts from customers included royalty and license income from partners including SSL International and Dade Behring (part of the Siemens Healthcare group), and grant and contract payments from the U.S. National Institutes of Health for VivaGel(R) development costs. The receipts from SSL International represent the first payment under the strategically important partnership with SSL International for the VivaGel(R) coated condom, which Starpharma has estimated will yield total receipts in excess of A$100m.
Apart from the VivaGel(R) coated condom and stand-alone products, the Company is continuing to focus on near-term commercial partnerships in areas such as drug delivery, cosmetics / personal care products and diagnostics.
Contact
Dr Jackie Fairley
Chief Executive Officer
TEL: +61-3-8532-2704
Ben Rogers
Company Secretary
TEL: +61-3-8532-2702
ben.rogers@starpharma.com
| ||
|
